Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
27 hedge funds and large institutions have $2.44M invested in Regulus Therapeutics in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 14 closing their positions.
25% more call options, than puts
Call options by funds: $5K | Put options by funds: $4K
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
2.7% more ownership
Funds ownership: 0.3% → 3% (+2.7%)
25% less funds holding
Funds holding: 36 → 27 (-9)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
93% less capital invested
Capital invested by funds: $35.1M → $2.44M (-$32.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$183K |
| 2 |
Bank of New York Mellon
New York
|
+$40.5K |
| 3 |
Two Sigma Investments
New York
|
+$36.8K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$32.7K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$20.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$4.03M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$783K |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$147K |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$97K |
| 5 |
SDIC
South Dakota Investment Council
Sioux Falls,
South Dakota
|
-$73K |
RGLS Hedge Fund Activity: Q4 2018 in Review
27 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2018, worth a combined $2.44M — down 93% from $35.1M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of RGLS and 6 opened new positions — a net loss of 8 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $183K. The largest seller was Boxer Capital, exiting entirely with an estimated $4.03M sold.
- 27 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2018, down from 36 in Q3 2018.
- Funds reported $2.44M of Regulus Therapeutics stock for Q4 2018, down 93% quarter-over-quarter.
- 6 funds opened new Regulus Therapeutics positions in Q4 2018 and 14 closed out, a net change of -8 holders.
- The largest Regulus Therapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $183K added.
- The largest Regulus Therapeutics seller in Q4 2018 was Boxer Capital, an estimated $4.03M sold.
Based on aggregated 13F filings for Q4 2018.